| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 191 | 2024 | 2150 | 13.460 |
Why?
|
| Adrenergic beta-Antagonists | 96 | 2025 | 316 | 11.980 |
Why?
|
| Propanolamines | 57 | 2021 | 96 | 7.220 |
Why?
|
| Cardiomyopathy, Dilated | 62 | 2025 | 372 | 7.090 |
Why?
|
| Myocardium | 107 | 2022 | 970 | 4.850 |
Why?
|
| Receptors, Adrenergic, beta-1 | 21 | 2021 | 46 | 4.440 |
Why?
|
| Stroke Volume | 43 | 2025 | 588 | 4.290 |
Why?
|
| Receptors, Adrenergic, beta | 57 | 2011 | 126 | 4.150 |
Why?
|
| Defibrillators, Implantable | 13 | 2022 | 295 | 3.190 |
Why?
|
| Cardiotonic Agents | 29 | 2011 | 124 | 3.080 |
Why?
|
| Ventricular Function, Left | 32 | 2025 | 525 | 3.070 |
Why?
|
| Carbazoles | 34 | 2009 | 84 | 2.880 |
Why?
|
| Polymorphism, Genetic | 17 | 2023 | 639 | 2.750 |
Why?
|
| Ventricular Remodeling | 12 | 2025 | 256 | 2.710 |
Why?
|
| Atrial Fibrillation | 9 | 2024 | 378 | 2.670 |
Why?
|
| Cardiac Resynchronization Therapy | 6 | 2022 | 45 | 2.670 |
Why?
|
| Heart Ventricles | 42 | 2024 | 766 | 2.630 |
Why?
|
| Cardiac Pacing, Artificial | 12 | 2009 | 84 | 2.590 |
Why?
|
| Cardiac Output, Low | 22 | 2006 | 66 | 2.370 |
Why?
|
| Heart | 48 | 2022 | 638 | 2.120 |
Why?
|
| Cardiomyopathies | 27 | 2024 | 335 | 1.990 |
Why?
|
| Heart Transplantation | 66 | 2017 | 710 | 1.920 |
Why?
|
| Metoprolol | 17 | 2019 | 39 | 1.800 |
Why?
|
| Ventricular Dysfunction, Left | 20 | 2018 | 386 | 1.650 |
Why?
|
| Phosphodiesterase Inhibitors | 12 | 2008 | 85 | 1.640 |
Why?
|
| Receptors, Adrenergic | 11 | 2023 | 34 | 1.620 |
Why?
|
| Myocardial Contraction | 38 | 2019 | 331 | 1.610 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 5 | 2018 | 17 | 1.600 |
Why?
|
| Myocytes, Cardiac | 17 | 2022 | 491 | 1.570 |
Why?
|
| Humans | 378 | 2025 | 128524 | 1.500 |
Why?
|
| Heart Rate | 24 | 2025 | 804 | 1.490 |
Why?
|
| Cardiovascular Agents | 7 | 2025 | 151 | 1.480 |
Why?
|
| Enoximone | 14 | 2010 | 17 | 1.470 |
Why?
|
| Dobutamine | 12 | 2018 | 36 | 1.320 |
Why?
|
| Ventricular Fibrillation | 5 | 2023 | 58 | 1.260 |
Why?
|
| Norepinephrine | 19 | 2023 | 209 | 1.260 |
Why?
|
| Middle Aged | 168 | 2025 | 30893 | 1.250 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2024 | 1358 | 1.180 |
Why?
|
| Electric Countershock | 6 | 2009 | 106 | 1.180 |
Why?
|
| Treatment Outcome | 50 | 2025 | 10163 | 1.150 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 9 | 2016 | 201 | 1.140 |
Why?
|
| Clinical Trials as Topic | 17 | 2024 | 998 | 1.140 |
Why?
|
| Receptors, Histamine H2 | 2 | 2017 | 8 | 1.120 |
Why?
|
| Aged | 92 | 2025 | 21971 | 1.120 |
Why?
|
| Male | 201 | 2025 | 62883 | 1.070 |
Why?
|
| Heart Injuries | 2 | 2024 | 35 | 1.060 |
Why?
|
| Hemodynamics | 39 | 2013 | 1083 | 1.040 |
Why?
|
| Hospitalization | 24 | 2016 | 2071 | 1.020 |
Why?
|
| RNA, Messenger | 26 | 2021 | 2674 | 1.020 |
Why?
|
| Vasodilator Agents | 12 | 2014 | 321 | 1.020 |
Why?
|
| Female | 193 | 2025 | 68127 | 1.000 |
Why?
|
| Gene Expression Regulation | 19 | 2020 | 2506 | 1.000 |
Why?
|
| Graft Rejection | 39 | 1996 | 557 | 0.990 |
Why?
|
| Pharmacogenetics | 8 | 2019 | 171 | 0.940 |
Why?
|
| Pacemaker, Artificial | 4 | 2009 | 109 | 0.930 |
Why?
|
| Signal Transduction | 27 | 2023 | 4829 | 0.890 |
Why?
|
| Clinical Trials Data Monitoring Committees | 3 | 2024 | 6 | 0.860 |
Why?
|
| Myocarditis | 2 | 2023 | 97 | 0.840 |
Why?
|
| Adrenergic beta-Agonists | 12 | 2006 | 129 | 0.830 |
Why?
|
| Adenylyl Cyclases | 24 | 1999 | 82 | 0.810 |
Why?
|
| Sympathetic Nervous System | 12 | 2020 | 184 | 0.800 |
Why?
|
| Muscle Proteins | 3 | 2025 | 228 | 0.800 |
Why?
|
| MicroRNAs | 7 | 2022 | 671 | 0.790 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2023 | 52 | 0.790 |
Why?
|
| Histamine H2 Antagonists | 5 | 2016 | 27 | 0.790 |
Why?
|
| Double-Blind Method | 29 | 2025 | 1860 | 0.770 |
Why?
|
| Electrocardiography | 13 | 2024 | 607 | 0.760 |
Why?
|
| Down-Regulation | 10 | 2015 | 629 | 0.760 |
Why?
|
| Cardiovascular System | 1 | 2023 | 139 | 0.750 |
Why?
|
| Diuretics | 2 | 2016 | 74 | 0.730 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2024 | 359 | 0.730 |
Why?
|
| Genetic Variation | 3 | 2017 | 934 | 0.710 |
Why?
|
| Atrial Flutter | 2 | 2017 | 35 | 0.700 |
Why?
|
| Multicenter Studies as Topic | 5 | 2024 | 285 | 0.700 |
Why?
|
| Myosin Heavy Chains | 12 | 2007 | 173 | 0.690 |
Why?
|
| Histone Deacetylases | 4 | 2011 | 209 | 0.690 |
Why?
|
| Biological Products | 1 | 2023 | 200 | 0.680 |
Why?
|
| Dose-Response Relationship, Drug | 29 | 2018 | 1943 | 0.670 |
Why?
|
| Gene Expression | 15 | 2021 | 1462 | 0.650 |
Why?
|
| Chronic Disease | 23 | 2016 | 1701 | 0.640 |
Why?
|
| Ventricular Function, Right | 7 | 2021 | 272 | 0.640 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 1 | 2019 | 14 | 0.630 |
Why?
|
| Cyclic AMP | 10 | 2019 | 230 | 0.630 |
Why?
|
| Mortality | 5 | 2019 | 307 | 0.620 |
Why?
|
| Receptors, Adrenergic, beta-2 | 7 | 2023 | 44 | 0.580 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2018 | 2065 | 0.570 |
Why?
|
| Adult | 111 | 2024 | 35315 | 0.570 |
Why?
|
| Antibodies, Monoclonal | 19 | 1996 | 1355 | 0.570 |
Why?
|
| Exercise Tolerance | 6 | 2009 | 269 | 0.560 |
Why?
|
| Genotype | 13 | 2021 | 1831 | 0.560 |
Why?
|
| Culture | 1 | 2018 | 125 | 0.550 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 6 | 2011 | 132 | 0.550 |
Why?
|
| Doxorubicin | 20 | 2000 | 322 | 0.540 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2017 | 112 | 0.530 |
Why?
|
| Heart Conduction System | 8 | 2007 | 94 | 0.520 |
Why?
|
| Proportional Hazards Models | 12 | 2019 | 1208 | 0.520 |
Why?
|
| Isoproterenol | 16 | 2006 | 107 | 0.510 |
Why?
|
| Magnetic Resonance Imaging, Cine | 4 | 2024 | 182 | 0.510 |
Why?
|
| Phenotype | 14 | 2025 | 3050 | 0.510 |
Why?
|
| Follow-Up Studies | 32 | 2024 | 4898 | 0.510 |
Why?
|
| Heart Diseases | 15 | 2006 | 345 | 0.510 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2016 | 90 | 0.500 |
Why?
|
| Prognosis | 17 | 2024 | 3780 | 0.500 |
Why?
|
| Spironolactone | 4 | 2021 | 28 | 0.500 |
Why?
|
| Receptors, Adrenergic, alpha | 8 | 2010 | 25 | 0.490 |
Why?
|
| Isosorbide Dinitrate | 2 | 2014 | 3 | 0.480 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2014 | 14 | 0.470 |
Why?
|
| Hydralazine | 1 | 2014 | 4 | 0.470 |
Why?
|
| Drug Discovery | 2 | 2015 | 130 | 0.460 |
Why?
|
| Aged, 80 and over | 26 | 2024 | 7040 | 0.460 |
Why?
|
| Animals | 79 | 2023 | 34501 | 0.460 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 4 | 2021 | 45 | 0.460 |
Why?
|
| Heart-Assist Devices | 7 | 2021 | 533 | 0.450 |
Why?
|
| Protein Kinase C | 4 | 2011 | 252 | 0.440 |
Why?
|
| Receptors, Thyroid Hormone | 4 | 2005 | 21 | 0.440 |
Why?
|
| European Union | 1 | 2013 | 10 | 0.430 |
Why?
|
| Gene Expression Profiling | 11 | 2021 | 1687 | 0.430 |
Why?
|
| GTP-Binding Proteins | 10 | 2001 | 155 | 0.430 |
Why?
|
| Prospective Studies | 31 | 2022 | 7043 | 0.420 |
Why?
|
| Catecholamines | 12 | 2022 | 97 | 0.420 |
Why?
|
| Myocardial Ischemia | 8 | 2018 | 249 | 0.420 |
Why?
|
| Immunosuppressive Agents | 18 | 1996 | 686 | 0.410 |
Why?
|
| Survival Analysis | 17 | 2018 | 1265 | 0.400 |
Why?
|
| Biomedical Research | 2 | 2018 | 646 | 0.400 |
Why?
|
| Genetic Testing | 4 | 2017 | 427 | 0.390 |
Why?
|
| Calcium | 19 | 2023 | 1178 | 0.380 |
Why?
|
| Cardiomegaly | 10 | 2022 | 170 | 0.370 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2011 | 21 | 0.370 |
Why?
|
| Adrenergic beta-1 Receptor Agonists | 1 | 2011 | 5 | 0.370 |
Why?
|
| Cause of Death | 4 | 2018 | 391 | 0.370 |
Why?
|
| United States Food and Drug Administration | 3 | 2024 | 198 | 0.370 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2024 | 2266 | 0.370 |
Why?
|
| Hypertension, Pulmonary | 9 | 2021 | 1735 | 0.360 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2011 | 43 | 0.360 |
Why?
|
| Survival Rate | 15 | 2011 | 1872 | 0.360 |
Why?
|
| Drug Design | 1 | 2012 | 155 | 0.360 |
Why?
|
| Tachycardia, Ventricular | 1 | 2012 | 169 | 0.360 |
Why?
|
| Sympathomimetics | 1 | 2010 | 21 | 0.360 |
Why?
|
| Aptamers, Nucleotide | 1 | 2011 | 78 | 0.360 |
Why?
|
| Calcium-Binding Proteins | 3 | 2021 | 211 | 0.340 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2024 | 71 | 0.340 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2009 | 113 | 0.340 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2009 | 283 | 0.330 |
Why?
|
| Models, Cardiovascular | 4 | 2005 | 190 | 0.330 |
Why?
|
| United States | 25 | 2024 | 13876 | 0.330 |
Why?
|
| RNA, Long Noncoding | 2 | 2022 | 178 | 0.330 |
Why?
|
| Drug Approval | 2 | 2015 | 86 | 0.330 |
Why?
|
| Rats | 22 | 2022 | 5168 | 0.320 |
Why?
|
| Diagnostic Test Approval | 1 | 2008 | 2 | 0.320 |
Why?
|
| Mice, Transgenic | 9 | 2023 | 2069 | 0.310 |
Why?
|
| Peptidyl-Dipeptidase A | 6 | 2003 | 51 | 0.310 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2008 | 3 | 0.310 |
Why?
|
| Atrial Natriuretic Factor | 7 | 2010 | 56 | 0.310 |
Why?
|
| Phosphorylation | 5 | 2021 | 1681 | 0.310 |
Why?
|
| Global Health | 1 | 2011 | 326 | 0.310 |
Why?
|
| Edema, Cardiac | 2 | 2007 | 3 | 0.300 |
Why?
|
| Disease Progression | 11 | 2014 | 2603 | 0.300 |
Why?
|
| Pharmacogenomic Testing | 2 | 2019 | 59 | 0.300 |
Why?
|
| Cardiomyopathy, Hypertrophic | 4 | 2021 | 131 | 0.300 |
Why?
|
| Milrinone | 4 | 2001 | 29 | 0.300 |
Why?
|
| Receptors, Angiotensin | 2 | 1998 | 12 | 0.300 |
Why?
|
| Heart Failure, Systolic | 1 | 2008 | 25 | 0.290 |
Why?
|
| Multivariate Analysis | 12 | 2015 | 1494 | 0.280 |
Why?
|
| Gene Regulatory Networks | 2 | 2023 | 281 | 0.280 |
Why?
|
| Coronary Circulation | 8 | 2010 | 136 | 0.270 |
Why?
|
| Adrenergic alpha-Antagonists | 3 | 2004 | 32 | 0.270 |
Why?
|
| Retrospective Studies | 22 | 2024 | 14460 | 0.270 |
Why?
|
| Bundle-Branch Block | 1 | 2006 | 30 | 0.260 |
Why?
|
| Echocardiography | 8 | 2019 | 625 | 0.260 |
Why?
|
| Drug Therapy, Combination | 14 | 2002 | 1009 | 0.260 |
Why?
|
| Ventricular Dysfunction, Right | 4 | 2021 | 224 | 0.260 |
Why?
|
| Time Factors | 29 | 2023 | 6503 | 0.260 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 90 | 0.250 |
Why?
|
| Cells, Cultured | 14 | 2022 | 4008 | 0.250 |
Why?
|
| Biopsy | 16 | 2017 | 1085 | 0.250 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2006 | 181 | 0.240 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 3 | 2018 | 10 | 0.240 |
Why?
|
| Neuropeptide Y | 4 | 1992 | 14 | 0.240 |
Why?
|
| Mutation | 6 | 2021 | 3692 | 0.240 |
Why?
|
| Case-Control Studies | 6 | 2023 | 3326 | 0.240 |
Why?
|
| In Vitro Techniques | 19 | 1996 | 1043 | 0.240 |
Why?
|
| Biomarkers | 8 | 2021 | 3881 | 0.240 |
Why?
|
| Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 32 | 0.240 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 411 | 0.240 |
Why?
|
| Calcium-Transporting ATPases | 6 | 2002 | 35 | 0.240 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2024 | 27 | 0.240 |
Why?
|
| Research Personnel | 2 | 2020 | 160 | 0.230 |
Why?
|
| Fibrosis | 3 | 2022 | 522 | 0.230 |
Why?
|
| Renin-Angiotensin System | 5 | 2021 | 80 | 0.230 |
Why?
|
| Imidazoles | 6 | 2005 | 228 | 0.230 |
Why?
|
| Ventricular Myosins | 5 | 2005 | 36 | 0.230 |
Why?
|
| Combined Modality Therapy | 5 | 2009 | 1209 | 0.230 |
Why?
|
| Adolescent | 36 | 2023 | 20213 | 0.230 |
Why?
|
| Blood Pressure | 16 | 2009 | 1733 | 0.230 |
Why?
|
| Mice | 18 | 2023 | 16579 | 0.230 |
Why?
|
| Potassium Channels | 1 | 2025 | 143 | 0.230 |
Why?
|
| Models, Biological | 9 | 2021 | 1693 | 0.220 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2022 | 317 | 0.220 |
Why?
|
| Computed Tomography Angiography | 1 | 2024 | 112 | 0.220 |
Why?
|
| Autoantibodies | 1 | 2011 | 1463 | 0.220 |
Why?
|
| Receptors, Endothelin | 2 | 2009 | 49 | 0.220 |
Why?
|
| Cohort Studies | 10 | 2022 | 5369 | 0.210 |
Why?
|
| Quinolones | 2 | 1996 | 122 | 0.210 |
Why?
|
| Colforsin | 5 | 1991 | 50 | 0.210 |
Why?
|
| Electrocardiography, Ambulatory | 5 | 2010 | 57 | 0.210 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2024 | 117 | 0.210 |
Why?
|
| Coronary Artery Disease | 3 | 2015 | 677 | 0.200 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2023 | 82 | 0.200 |
Why?
|
| Antifibrinolytic Agents | 1 | 2023 | 48 | 0.200 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2011 | 179 | 0.200 |
Why?
|
| Lamin Type A | 2 | 2021 | 48 | 0.200 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2011 | 756 | 0.200 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2023 | 182 | 0.200 |
Why?
|
| Quality of Life | 8 | 2009 | 2680 | 0.190 |
Why?
|
| Cadherin Related Proteins | 1 | 2022 | 12 | 0.190 |
Why?
|
| Angiotensin II | 5 | 2003 | 93 | 0.190 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 2 | 2019 | 10 | 0.190 |
Why?
|
| Antihypertensive Agents | 4 | 2010 | 486 | 0.190 |
Why?
|
| Virus Shedding | 1 | 2022 | 41 | 0.190 |
Why?
|
| Aortic Valve Stenosis | 1 | 2024 | 218 | 0.190 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 5 | 2021 | 37 | 0.190 |
Why?
|
| Cytokines | 4 | 2013 | 1985 | 0.190 |
Why?
|
| Protein Isoforms | 8 | 2022 | 375 | 0.190 |
Why?
|
| Psychometrics | 2 | 2024 | 681 | 0.190 |
Why?
|
| Histamine | 11 | 1990 | 64 | 0.190 |
Why?
|
| Carrier Proteins | 2 | 2022 | 731 | 0.190 |
Why?
|
| Iodocyanopindolol | 8 | 1992 | 11 | 0.190 |
Why?
|
| Pindolol | 8 | 1992 | 15 | 0.190 |
Why?
|
| Europe | 3 | 2018 | 362 | 0.190 |
Why?
|
| Blood Coagulation Disorders | 1 | 2023 | 162 | 0.190 |
Why?
|
| Disease Models, Animal | 13 | 2022 | 3943 | 0.180 |
Why?
|
| Virus Internalization | 1 | 2021 | 46 | 0.180 |
Why?
|
| Pharmacogenomic Variants | 2 | 2019 | 35 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2006 | 937 | 0.180 |
Why?
|
| Tetralones | 3 | 1990 | 4 | 0.180 |
Why?
|
| Rituximab | 1 | 2022 | 163 | 0.180 |
Why?
|
| Epoxy Compounds | 1 | 2000 | 32 | 0.180 |
Why?
|
| Vasoactive Intestinal Peptide | 3 | 1989 | 12 | 0.180 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2021 | 257 | 0.180 |
Why?
|
| Gene Frequency | 2 | 2014 | 504 | 0.180 |
Why?
|
| Risk Factors | 13 | 2021 | 9727 | 0.170 |
Why?
|
| Animals, Newborn | 4 | 2011 | 805 | 0.170 |
Why?
|
| Kidney Diseases | 2 | 2021 | 368 | 0.170 |
Why?
|
| Dopamine | 3 | 1992 | 285 | 0.170 |
Why?
|
| Piperazines | 2 | 2008 | 334 | 0.170 |
Why?
|
| Alternative Splicing | 1 | 2022 | 218 | 0.170 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2013 | 99 | 0.170 |
Why?
|
| Cell Adhesion | 2 | 2018 | 444 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2023 | 391 | 0.170 |
Why?
|
| Pulmonary Circulation | 2 | 2021 | 415 | 0.170 |
Why?
|
| Endocardium | 6 | 1995 | 33 | 0.170 |
Why?
|
| Research | 2 | 2020 | 409 | 0.170 |
Why?
|
| Software | 2 | 2015 | 610 | 0.170 |
Why?
|
| Reference Values | 7 | 2008 | 780 | 0.170 |
Why?
|
| Health Care Costs | 3 | 2005 | 395 | 0.170 |
Why?
|
| Sympatholytics | 5 | 2003 | 14 | 0.170 |
Why?
|
| Health Status Indicators | 3 | 2010 | 168 | 0.170 |
Why?
|
| Muromonab-CD3 | 13 | 1994 | 20 | 0.160 |
Why?
|
| Carteolol | 1 | 1999 | 1 | 0.160 |
Why?
|
| Calcium Channel Blockers | 3 | 1993 | 124 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 274 | 0.160 |
Why?
|
| Epinephrine | 4 | 1995 | 137 | 0.160 |
Why?
|
| Receptors, Gastrointestinal Hormone | 2 | 1989 | 6 | 0.160 |
Why?
|
| Diabetes Mellitus | 1 | 2007 | 1001 | 0.160 |
Why?
|
| Ventricular Function | 6 | 2006 | 60 | 0.160 |
Why?
|
| Systole | 5 | 2011 | 191 | 0.160 |
Why?
|
| Tissue Fixation | 1 | 1998 | 34 | 0.160 |
Why?
|
| Heterozygote | 3 | 2021 | 266 | 0.150 |
Why?
|
| Heart Function Tests | 4 | 2008 | 60 | 0.150 |
Why?
|
| Mutation, Missense | 3 | 2005 | 317 | 0.150 |
Why?
|
| Hypotension | 1 | 1999 | 114 | 0.150 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 345 | 0.150 |
Why?
|
| Apoptosis | 6 | 2017 | 2437 | 0.150 |
Why?
|
| Computer Graphics | 2 | 2015 | 41 | 0.150 |
Why?
|
| Cell Membrane | 8 | 2002 | 722 | 0.150 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2017 | 326 | 0.150 |
Why?
|
| Echocardiography, Stress | 1 | 2018 | 20 | 0.150 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 223 | 0.150 |
Why?
|
| Registries | 3 | 2024 | 1878 | 0.150 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2017 | 17 | 0.150 |
Why?
|
| Tissue Donors | 7 | 1997 | 386 | 0.140 |
Why?
|
| Filamins | 1 | 2018 | 28 | 0.140 |
Why?
|
| Administration, Oral | 6 | 2009 | 757 | 0.140 |
Why?
|
| DNA | 5 | 2017 | 1392 | 0.140 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2018 | 42 | 0.140 |
Why?
|
| Statistics as Topic | 6 | 2010 | 304 | 0.140 |
Why?
|
| Catalytic Domain | 1 | 1998 | 217 | 0.140 |
Why?
|
| Intersectoral Collaboration | 1 | 2018 | 61 | 0.140 |
Why?
|
| Antilymphocyte Serum | 4 | 1990 | 63 | 0.140 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 281 | 0.140 |
Why?
|
| Immunity, Cellular | 2 | 2018 | 267 | 0.140 |
Why?
|
| Sarcoplasmic Reticulum | 4 | 2002 | 44 | 0.140 |
Why?
|
| Adenylate Cyclase Toxin | 3 | 1991 | 8 | 0.140 |
Why?
|
| Cardiac Output | 6 | 2001 | 155 | 0.140 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 3 | 2008 | 11 | 0.130 |
Why?
|
| Virulence Factors, Bordetella | 3 | 1991 | 19 | 0.130 |
Why?
|
| Pertussis Toxin | 3 | 1991 | 26 | 0.130 |
Why?
|
| Sex Factors | 4 | 2024 | 1949 | 0.130 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2010 | 66 | 0.130 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 78 | 0.130 |
Why?
|
| Transcriptome | 2 | 2020 | 881 | 0.130 |
Why?
|
| Coronary Artery Bypass | 4 | 2015 | 222 | 0.130 |
Why?
|
| Hyperkalemia | 1 | 2016 | 26 | 0.130 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2016 | 11 | 0.130 |
Why?
|
| Molecular Sequence Data | 8 | 2006 | 2818 | 0.130 |
Why?
|
| Age Factors | 3 | 2015 | 3117 | 0.130 |
Why?
|
| Diastole | 3 | 2014 | 151 | 0.130 |
Why?
|
| Risk Assessment | 5 | 2009 | 3256 | 0.130 |
Why?
|
| Receptors, Histamine | 3 | 1987 | 5 | 0.130 |
Why?
|
| Young Adult | 5 | 2023 | 12320 | 0.130 |
Why?
|
| Binding, Competitive | 7 | 1992 | 199 | 0.130 |
Why?
|
| Oxygen Consumption | 5 | 2004 | 675 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 175 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 507 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2012 | 857 | 0.120 |
Why?
|
| Radioligand Assay | 6 | 1998 | 46 | 0.120 |
Why?
|
| Cell Differentiation | 3 | 2021 | 1883 | 0.120 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2015 | 18 | 0.120 |
Why?
|
| Pedigree | 6 | 2021 | 485 | 0.120 |
Why?
|
| Severity of Illness Index | 8 | 2008 | 2736 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 8 | 2003 | 1019 | 0.120 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2015 | 11 | 0.120 |
Why?
|
| Receptors, Nicotinic | 2 | 1990 | 322 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 148 | 0.120 |
Why?
|
| Vaccination | 1 | 2023 | 1336 | 0.120 |
Why?
|
| Cyclophosphamide | 5 | 1996 | 231 | 0.120 |
Why?
|
| Cholesterol | 3 | 2015 | 406 | 0.110 |
Why?
|
| Research Design | 4 | 2022 | 1038 | 0.110 |
Why?
|
| Sarcomeres | 3 | 2023 | 92 | 0.110 |
Why?
|
| Exercise Test | 7 | 2004 | 615 | 0.110 |
Why?
|
| Histamine Release | 3 | 1983 | 20 | 0.110 |
Why?
|
| Linoleoyl-CoA Desaturase | 1 | 2013 | 3 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2021 | 2245 | 0.110 |
Why?
|
| Kidney | 2 | 2021 | 1305 | 0.110 |
Why?
|
| Cardiovascular Diseases | 4 | 2021 | 2018 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2024 | 1936 | 0.110 |
Why?
|
| Enzyme Activation | 4 | 2011 | 799 | 0.110 |
Why?
|
| Kinetics | 9 | 1997 | 1616 | 0.110 |
Why?
|
| Coronary Disease | 10 | 1992 | 384 | 0.110 |
Why?
|
| Paris | 1 | 2013 | 1 | 0.110 |
Why?
|
| Transcription Factors | 3 | 2009 | 1631 | 0.110 |
Why?
|
| Vascular Resistance | 4 | 2007 | 369 | 0.110 |
Why?
|
| Lymphocytes | 3 | 1992 | 366 | 0.110 |
Why?
|
| Feasibility Studies | 3 | 2024 | 860 | 0.110 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1993 | 39 | 0.110 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1993 | 33 | 0.110 |
Why?
|
| Dipeptides | 1 | 1993 | 48 | 0.110 |
Why?
|
| Patient Safety | 1 | 2016 | 290 | 0.110 |
Why?
|
| Opportunistic Infections | 1 | 1993 | 47 | 0.110 |
Why?
|
| Prednisone | 5 | 1996 | 236 | 0.110 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2013 | 95 | 0.110 |
Why?
|
| Rabbits | 14 | 2005 | 761 | 0.100 |
Why?
|
| Azathioprine | 6 | 1996 | 49 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 82 | 0.100 |
Why?
|
| Drug Interactions | 6 | 2002 | 360 | 0.100 |
Why?
|
| Diltiazem | 9 | 1993 | 24 | 0.100 |
Why?
|
| DNA-Binding Proteins | 3 | 2005 | 1415 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1998 | 1190 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 3 | 1998 | 567 | 0.100 |
Why?
|
| Drug Administration Schedule | 6 | 2007 | 757 | 0.100 |
Why?
|
| Endothelins | 2 | 2010 | 59 | 0.100 |
Why?
|
| Myogenic Regulatory Factors | 2 | 2009 | 56 | 0.100 |
Why?
|
| Betaxolol | 1 | 1992 | 2 | 0.100 |
Why?
|
| MEF2 Transcription Factors | 2 | 2009 | 62 | 0.100 |
Why?
|
| Blood Vessels | 2 | 1993 | 184 | 0.100 |
Why?
|
| Regression Analysis | 5 | 2009 | 983 | 0.100 |
Why?
|
| von Willebrand Factor | 1 | 2012 | 62 | 0.100 |
Why?
|
| Exercise | 3 | 2009 | 1937 | 0.100 |
Why?
|
| Coronary Vasospasm | 5 | 1983 | 6 | 0.100 |
Why?
|
| Homozygote | 1 | 2012 | 191 | 0.100 |
Why?
|
| Bisoprolol | 2 | 2003 | 4 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2012 | 163 | 0.100 |
Why?
|
| Phospholipids | 1 | 2013 | 209 | 0.100 |
Why?
|
| Cost of Illness | 1 | 1994 | 288 | 0.100 |
Why?
|
| Hypertension | 3 | 1999 | 1238 | 0.100 |
Why?
|
| Hyperammonemia | 1 | 2011 | 16 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2000 | 1214 | 0.100 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2011 | 26 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 512 | 0.090 |
Why?
|
| Death | 1 | 2012 | 122 | 0.090 |
Why?
|
| Propranolol | 8 | 2000 | 49 | 0.090 |
Why?
|
| YY1 Transcription Factor | 3 | 2006 | 28 | 0.090 |
Why?
|
| Receptors, Purinergic | 1 | 1991 | 21 | 0.090 |
Why?
|
| Caveolin 3 | 1 | 2010 | 3 | 0.090 |
Why?
|
| Heart Septum | 1 | 2011 | 26 | 0.090 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 2 | 2001 | 2 | 0.090 |
Why?
|
| Muscular Diseases | 1 | 2011 | 110 | 0.090 |
Why?
|
| Phenylephrine | 6 | 2021 | 72 | 0.090 |
Why?
|
| Gallopamil | 4 | 1984 | 4 | 0.090 |
Why?
|
| Cardiac Catheterization | 10 | 1996 | 512 | 0.090 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2010 | 2 | 0.090 |
Why?
|
| Heparin | 2 | 2023 | 240 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 4 | 1990 | 518 | 0.090 |
Why?
|
| Verapamil | 4 | 1984 | 38 | 0.090 |
Why?
|
| Medicare | 2 | 1994 | 718 | 0.090 |
Why?
|
| Hospital Records | 1 | 2010 | 10 | 0.090 |
Why?
|
| Denervation | 1 | 1990 | 20 | 0.090 |
Why?
|
| Dogs | 8 | 1991 | 366 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2022 | 155 | 0.090 |
Why?
|
| Cyclosporins | 6 | 1990 | 59 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 2 | 1992 | 187 | 0.090 |
Why?
|
| Vincristine | 2 | 1987 | 110 | 0.080 |
Why?
|
| Hospital Costs | 3 | 2005 | 116 | 0.080 |
Why?
|
| Microcirculation | 1 | 2010 | 137 | 0.080 |
Why?
|
| Transplantation Immunology | 1 | 1990 | 33 | 0.080 |
Why?
|
| Premedication | 2 | 1994 | 40 | 0.080 |
Why?
|
| Myofibrils | 2 | 2021 | 50 | 0.080 |
Why?
|
| MADS Domain Proteins | 1 | 2009 | 5 | 0.080 |
Why?
|
| Cyclic GMP | 2 | 2008 | 85 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 3 | 2005 | 1490 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2015 | 1268 | 0.080 |
Why?
|
| Cell Line | 4 | 2021 | 2731 | 0.080 |
Why?
|
| Linear Models | 2 | 2010 | 816 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2003 | 685 | 0.080 |
Why?
|
| Hypertrophy | 3 | 2010 | 114 | 0.080 |
Why?
|
| Probability | 2 | 2008 | 308 | 0.080 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2010 | 132 | 0.080 |
Why?
|
| Amino Acid Sequence | 4 | 2006 | 2041 | 0.080 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 1 | 1 | 2008 | 3 | 0.080 |
Why?
|
| Antibodies | 1 | 1991 | 391 | 0.080 |
Why?
|
| Cell Nucleus | 2 | 2009 | 579 | 0.080 |
Why?
|
| Sildenafil Citrate | 1 | 2008 | 59 | 0.080 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 428 | 0.080 |
Why?
|
| Enzyme Inhibitors | 4 | 2013 | 811 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2022 | 3366 | 0.080 |
Why?
|
| Cricetinae | 2 | 2006 | 275 | 0.080 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2008 | 63 | 0.070 |
Why?
|
| Coronary Vessels | 8 | 2003 | 235 | 0.070 |
Why?
|
| Receptor, Angiotensin, Type 2 | 2 | 1998 | 9 | 0.070 |
Why?
|
| Sulfones | 1 | 2008 | 109 | 0.070 |
Why?
|
| Methylprednisolone | 3 | 1996 | 82 | 0.070 |
Why?
|
| Receptor, Angiotensin, Type 1 | 2 | 1998 | 21 | 0.070 |
Why?
|
| Anticoagulants | 2 | 2023 | 613 | 0.070 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2008 | 71 | 0.070 |
Why?
|
| Receptors, Histamine H1 | 2 | 1987 | 4 | 0.070 |
Why?
|
| Acute Disease | 3 | 2007 | 968 | 0.070 |
Why?
|
| Purines | 1 | 2008 | 169 | 0.070 |
Why?
|
| Acyclovir | 1 | 1988 | 93 | 0.070 |
Why?
|
| Iodine Radioisotopes | 2 | 2002 | 142 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 717 | 0.070 |
Why?
|
| Risk | 5 | 2004 | 852 | 0.070 |
Why?
|
| Desmin | 1 | 2007 | 24 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 1989 | 267 | 0.070 |
Why?
|
| Equipment Design | 1 | 2009 | 518 | 0.070 |
Why?
|
| Endothelin-1 | 1 | 2009 | 177 | 0.070 |
Why?
|
| Transplantation, Homologous | 5 | 1993 | 396 | 0.070 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2007 | 25 | 0.070 |
Why?
|
| Base Sequence | 5 | 1997 | 2134 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2008 | 634 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2005 | 269 | 0.070 |
Why?
|
| TRPC Cation Channels | 1 | 2006 | 12 | 0.070 |
Why?
|
| Calcium Channels | 4 | 1995 | 152 | 0.070 |
Why?
|
| Cardiolipins | 1 | 2007 | 81 | 0.070 |
Why?
|
| New York | 1 | 2006 | 123 | 0.070 |
Why?
|
| Incidence | 3 | 2007 | 2619 | 0.070 |
Why?
|
| Sheep | 1 | 1989 | 827 | 0.070 |
Why?
|
| Shock, Cardiogenic | 1 | 2006 | 59 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2010 | 844 | 0.070 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2006 | 67 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 2 | 1990 | 492 | 0.060 |
Why?
|
| Actins | 2 | 2006 | 401 | 0.060 |
Why?
|
| Amino Acid Motifs | 1 | 2006 | 209 | 0.060 |
Why?
|
| Calcineurin | 1 | 2006 | 91 | 0.060 |
Why?
|
| Infusions, Intravenous | 4 | 2007 | 384 | 0.060 |
Why?
|
| Child | 10 | 2021 | 20721 | 0.060 |
Why?
|
| Fenofibrate | 1 | 2005 | 31 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 1984 | 120 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2006 | 368 | 0.060 |
Why?
|
| Infant | 4 | 2015 | 8913 | 0.060 |
Why?
|
| Thyroid Hormone Receptors alpha | 1 | 2005 | 1 | 0.060 |
Why?
|
| Peptides | 2 | 2008 | 909 | 0.060 |
Why?
|
| Neurosecretory Systems | 1 | 2005 | 30 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2022 | 2752 | 0.060 |
Why?
|
| Digitalis Glycosides | 1 | 2005 | 1 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2002 | 814 | 0.060 |
Why?
|
| Guanylyl Imidodiphosphate | 3 | 1992 | 5 | 0.060 |
Why?
|
| Synapses | 1 | 1989 | 385 | 0.060 |
Why?
|
| Drug Evaluation | 3 | 1991 | 80 | 0.060 |
Why?
|
| Cardiac Volume | 2 | 2012 | 12 | 0.060 |
Why?
|
| DNA Mutational Analysis | 3 | 2018 | 386 | 0.060 |
Why?
|
| Thyroid Hormones | 1 | 2005 | 54 | 0.060 |
Why?
|
| Cell Compartmentation | 1 | 2005 | 51 | 0.060 |
Why?
|
| Recovery of Function | 1 | 2009 | 643 | 0.060 |
Why?
|
| Antigens, Nuclear | 1 | 2004 | 20 | 0.060 |
Why?
|
| Brain | 1 | 2017 | 2618 | 0.060 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2005 | 71 | 0.060 |
Why?
|
| Calcium Channels, L-Type | 1 | 2006 | 113 | 0.060 |
Why?
|
| Patient Selection | 4 | 2006 | 661 | 0.060 |
Why?
|
| PPAR gamma | 1 | 2005 | 182 | 0.060 |
Why?
|
| beta-Adrenergic Receptor Kinases | 2 | 2001 | 6 | 0.060 |
Why?
|
| Ethanolamines | 3 | 1990 | 18 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1986 | 113 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2015 | 10373 | 0.060 |
Why?
|
| Muscle, Smooth | 3 | 2001 | 145 | 0.060 |
Why?
|
| Diterpenes | 1 | 1984 | 32 | 0.060 |
Why?
|
| T-Lymphocytes | 6 | 1992 | 1922 | 0.060 |
Why?
|
| Placebos | 1 | 2004 | 201 | 0.060 |
Why?
|
| Walking | 1 | 2009 | 494 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2008 | 727 | 0.060 |
Why?
|
| Likelihood Functions | 1 | 2004 | 136 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2006 | 309 | 0.060 |
Why?
|
| Pyridones | 2 | 1996 | 159 | 0.060 |
Why?
|
| Proteome | 1 | 2008 | 431 | 0.060 |
Why?
|
| Body Weight | 3 | 1999 | 931 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 355 | 0.060 |
Why?
|
| Animals, Genetically Modified | 1 | 2005 | 232 | 0.060 |
Why?
|
| Carboxypeptidases | 1 | 2003 | 13 | 0.060 |
Why?
|
| Phenethylamines | 3 | 1990 | 23 | 0.050 |
Why?
|
| DNA Primers | 3 | 2011 | 510 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2004 | 136 | 0.050 |
Why?
|
| Organ Size | 3 | 2010 | 440 | 0.050 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2006 | 175 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 2002 | 123 | 0.050 |
Why?
|
| Genome, Human | 1 | 2006 | 392 | 0.050 |
Why?
|
| Nuclear Lamina | 1 | 2003 | 10 | 0.050 |
Why?
|
| Carbohydrate Epimerases | 1 | 2003 | 2 | 0.050 |
Why?
|
| Thromboplastin | 1 | 2023 | 69 | 0.050 |
Why?
|
| Benzazepines | 4 | 1985 | 40 | 0.050 |
Why?
|
| Precision Medicine | 2 | 2019 | 383 | 0.050 |
Why?
|
| Nitroglycerin | 3 | 2001 | 19 | 0.050 |
Why?
|
| Reperfusion Injury | 1 | 2005 | 262 | 0.050 |
Why?
|
| Digoxin | 1 | 2003 | 30 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 1988 | 339 | 0.050 |
Why?
|
| Morbidity | 2 | 2022 | 302 | 0.050 |
Why?
|
| American Heart Association | 2 | 2022 | 309 | 0.050 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2002 | 11 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2005 | 579 | 0.050 |
Why?
|
| Health Status | 1 | 2007 | 751 | 0.050 |
Why?
|
| Defibrillators | 1 | 2022 | 17 | 0.050 |
Why?
|
| Culture Techniques | 2 | 1992 | 81 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2022 | 148 | 0.050 |
Why?
|
| Drug Tolerance | 2 | 1997 | 82 | 0.050 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2003 | 127 | 0.050 |
Why?
|
| Daunorubicin | 2 | 1978 | 25 | 0.050 |
Why?
|
| RNA Splicing Factors | 1 | 2022 | 51 | 0.050 |
Why?
|
| Massachusetts | 1 | 2022 | 158 | 0.050 |
Why?
|
| Blotting, Western | 4 | 2008 | 1168 | 0.050 |
Why?
|
| Xamoterol | 1 | 2001 | 1 | 0.050 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2001 | 12 | 0.050 |
Why?
|
| Prevalence | 4 | 2018 | 2549 | 0.050 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2003 | 116 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2002 | 129 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2003 | 224 | 0.050 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 160 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2022 | 67 | 0.050 |
Why?
|
| Urticaria | 1 | 1982 | 37 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 2 | 1981 | 128 | 0.050 |
Why?
|
| Aging | 3 | 2007 | 1770 | 0.050 |
Why?
|
| Postoperative Complications | 6 | 1994 | 2479 | 0.050 |
Why?
|
| Adrenergic Antagonists | 1 | 2001 | 8 | 0.050 |
Why?
|
| Neuropilin-1 | 1 | 2021 | 8 | 0.050 |
Why?
|
| Virus Attachment | 1 | 2021 | 16 | 0.050 |
Why?
|
| Serum Response Factor | 1 | 2021 | 31 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2000 | 2058 | 0.050 |
Why?
|
| Autophagy | 1 | 2023 | 266 | 0.050 |
Why?
|
| Actuarial Analysis | 3 | 1991 | 25 | 0.050 |
Why?
|
| Fetal Proteins | 1 | 2001 | 16 | 0.050 |
Why?
|
| Contraindications | 1 | 2001 | 88 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 313 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 1669 | 0.050 |
Why?
|
| Troponin | 1 | 2021 | 50 | 0.050 |
Why?
|
| Rats, Inbred SHR | 2 | 2013 | 43 | 0.050 |
Why?
|
| Guanine Nucleotides | 2 | 1996 | 15 | 0.050 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2021 | 101 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2022 | 163 | 0.040 |
Why?
|
| Tissue Distribution | 2 | 2000 | 290 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2021 | 815 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 1999 | 190 | 0.040 |
Why?
|
| Logistic Models | 2 | 2012 | 1975 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2021 | 82 | 0.040 |
Why?
|
| Heart Atria | 3 | 1989 | 124 | 0.040 |
Why?
|
| Anaphylaxis | 1 | 1982 | 98 | 0.040 |
Why?
|
| Culture Media | 1 | 2021 | 167 | 0.040 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2000 | 45 | 0.040 |
Why?
|
| Return to Sport | 1 | 2021 | 91 | 0.040 |
Why?
|
| Postoperative Care | 3 | 1992 | 243 | 0.040 |
Why?
|
| Ganciclovir | 2 | 1992 | 51 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2022 | 195 | 0.040 |
Why?
|
| Ion Channels | 2 | 1996 | 127 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 1 | 2001 | 229 | 0.040 |
Why?
|
| Cardiology | 2 | 2010 | 267 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 107 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 466 | 0.040 |
Why?
|
| Health Resources | 1 | 2001 | 120 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2002 | 479 | 0.040 |
Why?
|
| Viral Load | 1 | 2022 | 450 | 0.040 |
Why?
|
| Immune System | 1 | 2021 | 177 | 0.040 |
Why?
|
| Preoperative Care | 3 | 1992 | 342 | 0.040 |
Why?
|
| Furazolidone | 1 | 1999 | 1 | 0.040 |
Why?
|
| Angina Pectoris, Variant | 4 | 1983 | 5 | 0.040 |
Why?
|
| Creatine Kinase | 3 | 1991 | 75 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2000 | 291 | 0.040 |
Why?
|
| Turkey | 1 | 1999 | 18 | 0.040 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1999 | 15 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2022 | 425 | 0.040 |
Why?
|
| Sensory Receptor Cells | 2 | 1970 | 93 | 0.040 |
Why?
|
| Receptors, Vasoactive Intestinal Peptide | 2 | 1989 | 4 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2005 | 1108 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 184 | 0.040 |
Why?
|
| Models, Genetic | 2 | 2015 | 590 | 0.040 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2000 | 174 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2007 | 2262 | 0.040 |
Why?
|
| Potassium Compounds | 1 | 1998 | 7 | 0.040 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 1992 | 171 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2001 | 235 | 0.040 |
Why?
|
| Collagenases | 1 | 1998 | 23 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2023 | 644 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 235 | 0.040 |
Why?
|
| Hydroxides | 1 | 1998 | 26 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 1999 | 301 | 0.040 |
Why?
|
| Necrosis | 2 | 1997 | 231 | 0.040 |
Why?
|
| Computational Biology | 2 | 2015 | 597 | 0.040 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1999 | 67 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 681 | 0.040 |
Why?
|
| Autopsy | 1 | 1998 | 92 | 0.040 |
Why?
|
| Carbachol | 3 | 1988 | 20 | 0.040 |
Why?
|
| Membranes | 2 | 1991 | 20 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2020 | 478 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 2 | 2015 | 335 | 0.040 |
Why?
|
| CD3 Complex | 2 | 1996 | 101 | 0.040 |
Why?
|
| Aldosterone | 1 | 1998 | 42 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2021 | 413 | 0.040 |
Why?
|
| Practolol | 1 | 1977 | 1 | 0.040 |
Why?
|
| Histamine H1 Antagonists | 3 | 1990 | 29 | 0.040 |
Why?
|
| Chick Embryo | 2 | 2001 | 130 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2005 | 581 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2022 | 939 | 0.040 |
Why?
|
| Diazoxide | 1 | 1977 | 23 | 0.040 |
Why?
|
| Dihydroalprenolol | 4 | 1988 | 4 | 0.040 |
Why?
|
| Zebrafish | 1 | 2022 | 464 | 0.040 |
Why?
|
| Collagen | 1 | 2020 | 429 | 0.040 |
Why?
|
| Fluorides | 2 | 1991 | 49 | 0.040 |
Why?
|
| Guanosine Triphosphate | 2 | 1991 | 92 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 681 | 0.030 |
Why?
|
| Magnesium | 1 | 1977 | 151 | 0.030 |
Why?
|
| Sodium | 1 | 1998 | 205 | 0.030 |
Why?
|
| Stimulation, Chemical | 2 | 1990 | 62 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2005 | 1266 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 1999 | 470 | 0.030 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein D | 1 | 1996 | 3 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1997 | 123 | 0.030 |
Why?
|
| Veratridine | 1 | 1996 | 6 | 0.030 |
Why?
|
| Sotalol | 1 | 1996 | 6 | 0.030 |
Why?
|
| Azetidines | 1 | 1996 | 40 | 0.030 |
Why?
|
| Nitroprusside | 1 | 1995 | 66 | 0.030 |
Why?
|
| Neoplasms | 4 | 2000 | 2465 | 0.030 |
Why?
|
| Cell Survival | 1 | 1999 | 1077 | 0.030 |
Why?
|
| Organ Specificity | 2 | 2008 | 291 | 0.030 |
Why?
|
| Physical Exertion | 1 | 1996 | 212 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 773 | 0.030 |
Why?
|
| Federal Government | 1 | 2015 | 26 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 485 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 1995 | 38 | 0.030 |
Why?
|
| Angina Pectoris | 3 | 1985 | 67 | 0.030 |
Why?
|
| Government Regulation | 1 | 2015 | 49 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1995 | 22 | 0.030 |
Why?
|
| Quinolines | 2 | 1993 | 149 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 1996 | 530 | 0.030 |
Why?
|
| Decision Trees | 1 | 2015 | 89 | 0.030 |
Why?
|
| Guinea Pigs | 2 | 1985 | 156 | 0.030 |
Why?
|
| Naphthacenes | 2 | 1984 | 5 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1999 | 732 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 3 | 1993 | 288 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 2 | 2007 | 402 | 0.030 |
Why?
|
| Erythroid-Specific DNA-Binding Factors | 2 | 2004 | 18 | 0.030 |
Why?
|
| Adenosine Diphosphate Ribose | 2 | 1991 | 7 | 0.030 |
Why?
|
| Phosphorus Radioisotopes | 2 | 1991 | 28 | 0.030 |
Why?
|
| Dibenzylchlorethamine | 1 | 1973 | 1 | 0.030 |
Why?
|
| Antisense Elements (Genetics) | 1 | 1993 | 4 | 0.030 |
Why?
|
| Second Messenger Systems | 1 | 1994 | 32 | 0.030 |
Why?
|
| Data Mining | 1 | 2015 | 109 | 0.030 |
Why?
|
| Heart-Lung Transplantation | 1 | 1993 | 10 | 0.030 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 1991 | 57 | 0.030 |
Why?
|
| Angiotensin I | 2 | 2003 | 7 | 0.030 |
Why?
|
| Drug Industry | 1 | 2015 | 106 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2015 | 339 | 0.030 |
Why?
|
| Specialization | 1 | 1995 | 144 | 0.030 |
Why?
|
| Neurotransmitter Agents | 1 | 1994 | 80 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2015 | 214 | 0.030 |
Why?
|
| Lisinopril | 1 | 1993 | 15 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2006 | 836 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2011 | 1271 | 0.030 |
Why?
|
| Brain Death | 1 | 1993 | 46 | 0.030 |
Why?
|
| Graft Survival | 3 | 1994 | 503 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 1993 | 92 | 0.030 |
Why?
|
| Random Allocation | 3 | 1988 | 346 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 1992 | 22 | 0.030 |
Why?
|
| Action Potentials | 1 | 1996 | 469 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 1996 | 379 | 0.030 |
Why?
|
| Caspases | 1 | 2013 | 242 | 0.030 |
Why?
|
| Health Expenditures | 1 | 1994 | 184 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2011 | 1188 | 0.020 |
Why?
|
| Inflammation | 1 | 2023 | 2664 | 0.020 |
Why?
|
| Xenopus laevis | 1 | 1992 | 97 | 0.020 |
Why?
|
| Transfection | 2 | 2007 | 895 | 0.020 |
Why?
|
| Utah | 2 | 1992 | 65 | 0.020 |
Why?
|
| Solute Carrier Family 22 Member 5 | 1 | 2011 | 9 | 0.020 |
Why?
|
| Gastroesophageal Reflux | 1 | 2014 | 232 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 281 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1996 | 575 | 0.020 |
Why?
|
| Hypercholesterolemia | 2 | 1992 | 101 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 2521 | 0.020 |
Why?
|
| Assisted Circulation | 1 | 1992 | 25 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1995 | 723 | 0.020 |
Why?
|
| Education, Medical | 1 | 1995 | 244 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 5257 | 0.020 |
Why?
|
| Phenylisopropyladenosine | 1 | 1991 | 6 | 0.020 |
Why?
|
| Transposition of Great Vessels | 1 | 1991 | 34 | 0.020 |
Why?
|
| Adenosine-5'-(N-ethylcarboxamide) | 1 | 1991 | 10 | 0.020 |
Why?
|
| Adenylyl Cyclase Inhibitors | 1 | 1991 | 6 | 0.020 |
Why?
|
| Muscle Denervation | 1 | 1991 | 10 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2011 | 143 | 0.020 |
Why?
|
| Carnitine | 1 | 2011 | 76 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 1991 | 58 | 0.020 |
Why?
|
| Isoantigens | 1 | 1991 | 12 | 0.020 |
Why?
|
| Autoimmune Diseases | 2 | 2001 | 423 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 1991 | 162 | 0.020 |
Why?
|
| 5'-Nucleotidase | 1 | 1991 | 37 | 0.020 |
Why?
|
| Manganese | 1 | 1991 | 60 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2012 | 368 | 0.020 |
Why?
|
| Glycine | 1 | 2011 | 163 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2010 | 169 | 0.020 |
Why?
|
| Isradipine | 1 | 1990 | 4 | 0.020 |
Why?
|
| Nitrendipine | 1 | 1990 | 13 | 0.020 |
Why?
|
| Ergonovine | 4 | 1984 | 4 | 0.020 |
Why?
|
| Nerve Regeneration | 1 | 1990 | 62 | 0.020 |
Why?
|
| Oxadiazoles | 1 | 1990 | 34 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 1990 | 85 | 0.020 |
Why?
|
| Endothelium | 1 | 2010 | 106 | 0.020 |
Why?
|
| Arginine | 1 | 2011 | 258 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2010 | 417 | 0.020 |
Why?
|
| Giant Cell Arteritis | 1 | 1990 | 47 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1989 | 81 | 0.020 |
Why?
|
| Protein Binding | 2 | 2006 | 2097 | 0.020 |
Why?
|
| Adenosine | 1 | 1991 | 211 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1990 | 322 | 0.020 |
Why?
|
| Methotrexate | 1 | 1990 | 249 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2004 | 1199 | 0.020 |
Why?
|
| Endothelin-Converting Enzymes | 1 | 2009 | 10 | 0.020 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2009 | 26 | 0.020 |
Why?
|
| Androgens | 1 | 2010 | 174 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 3 | 1996 | 172 | 0.020 |
Why?
|
| Mitochondria, Heart | 2 | 2007 | 92 | 0.020 |
Why?
|
| Metalloendopeptidases | 1 | 2009 | 58 | 0.020 |
Why?
|
| 14-3-3 Proteins | 1 | 2008 | 17 | 0.020 |
Why?
|
| Phosphatidylinositols | 1 | 1988 | 57 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2008 | 46 | 0.020 |
Why?
|
| Immunization | 1 | 1991 | 411 | 0.020 |
Why?
|
| COS Cells | 1 | 2008 | 184 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2010 | 465 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2008 | 144 | 0.020 |
Why?
|
| Binding Sites | 2 | 1989 | 1239 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1988 | 42 | 0.020 |
Why?
|
| Hydroxydopamines | 1 | 1988 | 4 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 256 | 0.020 |
Why?
|
| Leukopenia | 1 | 1988 | 28 | 0.020 |
Why?
|
| Arteritis | 1 | 1988 | 24 | 0.020 |
Why?
|
| Tropomyosin | 1 | 2007 | 12 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 1990 | 582 | 0.020 |
Why?
|
| Patient Discharge | 1 | 1994 | 849 | 0.020 |
Why?
|
| Steroids | 1 | 1988 | 148 | 0.020 |
Why?
|
| Cations, Divalent | 2 | 1977 | 54 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 55 | 0.020 |
Why?
|
| Nausea | 1 | 1988 | 108 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2007 | 48 | 0.020 |
Why?
|
| Hospitals, Special | 1 | 1987 | 8 | 0.020 |
Why?
|
| Rats, Inbred BN | 1 | 2007 | 53 | 0.020 |
Why?
|
| Genetic Carrier Screening | 1 | 2007 | 25 | 0.020 |
Why?
|
| Cardiac Care Facilities | 1 | 1987 | 12 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1616 | 0.020 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2007 | 28 | 0.020 |
Why?
|
| Palliative Care | 1 | 1994 | 716 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2007 | 91 | 0.020 |
Why?
|
| Citrate (si)-Synthase | 1 | 2007 | 58 | 0.020 |
Why?
|
| Calcium Gluconate | 1 | 1986 | 4 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 471 | 0.020 |
Why?
|
| Electron Transport Complex IV | 1 | 2007 | 57 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 1989 | 260 | 0.020 |
Why?
|
| Estradiol | 1 | 2010 | 497 | 0.020 |
Why?
|
| Myocardial Infarction | 2 | 1985 | 1014 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2007 | 131 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 440 | 0.020 |
Why?
|
| Testosterone | 1 | 2010 | 378 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 4 | 1 | 2006 | 7 | 0.020 |
Why?
|
| Indole Alkaloids | 1 | 2006 | 8 | 0.020 |
Why?
|
| Antibody Formation | 3 | 1994 | 287 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2011 | 405 | 0.020 |
Why?
|
| Pressure | 2 | 1977 | 239 | 0.020 |
Why?
|
| Motor Activity | 2 | 2001 | 667 | 0.020 |
Why?
|
| Thiadiazoles | 1 | 2006 | 24 | 0.020 |
Why?
|
| Death, Sudden | 2 | 1983 | 24 | 0.020 |
Why?
|
| Protein Phosphatase 2 | 1 | 2006 | 37 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2000 | 2430 | 0.020 |
Why?
|
| NFATC Transcription Factors | 1 | 2006 | 78 | 0.020 |
Why?
|
| Anilides | 1 | 2006 | 72 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1987 | 327 | 0.020 |
Why?
|
| PPAR alpha | 1 | 2005 | 59 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2009 | 5346 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2006 | 258 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2005 | 41 | 0.020 |
Why?
|
| Swine | 2 | 2005 | 743 | 0.020 |
Why?
|
| Models, Economic | 1 | 2005 | 55 | 0.020 |
Why?
|
| Health Surveys | 1 | 2007 | 492 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2005 | 108 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 1987 | 301 | 0.020 |
Why?
|
| Catalase | 1 | 2005 | 122 | 0.020 |
Why?
|
| Sarcolemma | 1 | 1985 | 40 | 0.020 |
Why?
|
| Enalapril | 1 | 2005 | 16 | 0.020 |
Why?
|
| Ribonucleases | 1 | 2005 | 53 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2005 | 63 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 81 | 0.020 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2005 | 90 | 0.020 |
Why?
|
| Liver | 1 | 1993 | 1827 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2005 | 93 | 0.020 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2005 | 55 | 0.010 |
Why?
|
| Muscle Cells | 1 | 2005 | 39 | 0.010 |
Why?
|
| Ku Autoantigen | 1 | 2004 | 13 | 0.010 |
Why?
|
| HLA-DR Antigens | 3 | 1992 | 225 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 157 | 0.010 |
Why?
|
| Receptors, Drug | 1 | 1984 | 13 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 267 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2005 | 228 | 0.010 |
Why?
|
| Protein Transport | 1 | 2006 | 422 | 0.010 |
Why?
|
| Nicardipine | 1 | 1984 | 6 | 0.010 |
Why?
|
| Cytosol | 1 | 2005 | 213 | 0.010 |
Why?
|
| Nifedipine | 1 | 1984 | 28 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2005 | 190 | 0.010 |
Why?
|
| Pericardium | 1 | 1984 | 54 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 1991 | 871 | 0.010 |
Why?
|
| Family Health | 1 | 2005 | 194 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 1984 | 417 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2005 | 603 | 0.010 |
Why?
|
| Cromolyn Sodium | 1 | 1983 | 11 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2005 | 374 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 1984 | 41 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1984 | 197 | 0.010 |
Why?
|
| Oxygen | 1 | 1988 | 901 | 0.010 |
Why?
|
| Suppression, Genetic | 1 | 2003 | 25 | 0.010 |
Why?
|
| Calcium Chloride | 1 | 1983 | 14 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 2005 | 322 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 614 | 0.010 |
Why?
|
| Species Specificity | 1 | 1984 | 567 | 0.010 |
Why?
|
| Radionuclide Angiography | 1 | 2002 | 6 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 96 | 0.010 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2003 | 56 | 0.010 |
Why?
|
| Contractile Proteins | 1 | 1982 | 15 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 1984 | 186 | 0.010 |
Why?
|
| Hydroxyproline | 1 | 1982 | 22 | 0.010 |
Why?
|
| Tritium | 1 | 1982 | 75 | 0.010 |
Why?
|
| Heart Arrest, Induced | 1 | 1982 | 31 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2003 | 181 | 0.010 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2002 | 28 | 0.010 |
Why?
|
| Isometric Contraction | 1 | 1984 | 187 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 423 | 0.010 |
Why?
|
| Citrates | 2 | 1982 | 42 | 0.010 |
Why?
|
| Proteomics | 1 | 2008 | 1004 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 2001 | 44 | 0.010 |
Why?
|
| Stomach | 2 | 1973 | 109 | 0.010 |
Why?
|
| Histamine Antagonists | 1 | 1981 | 19 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2003 | 372 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1982 | 208 | 0.010 |
Why?
|
| Pyridines | 1 | 2005 | 469 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2001 | 26 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 1984 | 259 | 0.010 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2001 | 5 | 0.010 |
Why?
|
| Cadherins | 1 | 2003 | 186 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 475 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 179 | 0.010 |
Why?
|
| X Chromosome | 1 | 2001 | 51 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 176 | 0.010 |
Why?
|
| Spasm | 1 | 1980 | 19 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 313 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 826 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2001 | 299 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 2 | 1990 | 84 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2001 | 398 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2000 | 48 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2001 | 180 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2003 | 660 | 0.010 |
Why?
|
| Radionuclide Ventriculography | 1 | 1999 | 1 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 5040 | 0.010 |
Why?
|
| Arteries | 1 | 1981 | 266 | 0.010 |
Why?
|
| Protein Kinase C beta | 1 | 1999 | 21 | 0.010 |
Why?
|
| Creatinine | 2 | 1992 | 475 | 0.010 |
Why?
|
| Maleimides | 1 | 1999 | 21 | 0.010 |
Why?
|
| Protein Kinase C-epsilon | 1 | 1999 | 26 | 0.010 |
Why?
|
| Physical Conditioning, Animal | 1 | 2001 | 229 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 1999 | 37 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1999 | 206 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1999 | 292 | 0.010 |
Why?
|
| Phonocardiography | 1 | 1978 | 4 | 0.010 |
Why?
|
| Health Services Research | 1 | 2001 | 389 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1989 | 374 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1999 | 304 | 0.010 |
Why?
|
| Gluconates | 1 | 1977 | 5 | 0.010 |
Why?
|
| Disease Management | 1 | 2002 | 588 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1982 | 1416 | 0.010 |
Why?
|
| Blood Glucose | 2 | 1977 | 2092 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1998 | 145 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 1981 | 506 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 2335 | 0.010 |
Why?
|
| Electrolytes | 1 | 1977 | 58 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 1980 | 421 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1986 | 1565 | 0.010 |
Why?
|
| Myosins | 1 | 1997 | 133 | 0.010 |
Why?
|
| Polyribosomes | 1 | 1996 | 21 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 1996 | 78 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2001 | 718 | 0.010 |
Why?
|
| Indoles | 1 | 1999 | 367 | 0.010 |
Why?
|
| Anesthesia | 1 | 1977 | 129 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 1639 | 0.010 |
Why?
|
| Length of Stay | 1 | 2001 | 1121 | 0.010 |
Why?
|
| Cilazapril | 1 | 1995 | 2 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1995 | 26 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 1996 | 656 | 0.010 |
Why?
|
| Remission Induction | 1 | 1995 | 269 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1973 | 35 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1997 | 581 | 0.010 |
Why?
|
| Immunity | 1 | 1994 | 131 | 0.010 |
Why?
|
| Endomyocardial Fibrosis | 1 | 1993 | 3 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1993 | 85 | 0.010 |
Why?
|
| Bilirubin | 1 | 1993 | 92 | 0.010 |
Why?
|
| Mechlorethamine | 1 | 1973 | 56 | 0.010 |
Why?
|
| Recurrence | 1 | 1996 | 1001 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1996 | 384 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1993 | 150 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1993 | 109 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1996 | 1284 | 0.010 |
Why?
|
| Pyrazines | 1 | 1993 | 88 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1992 | 120 | 0.010 |
Why?
|
| Educational Measurement | 1 | 1995 | 261 | 0.010 |
Why?
|
| Informed Consent | 1 | 1993 | 174 | 0.010 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 1992 | 16 | 0.010 |
Why?
|
| Safety | 1 | 1993 | 329 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2003 | 5687 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1992 | 153 | 0.010 |
Why?
|
| Histocompatibility | 1 | 1991 | 26 | 0.010 |
Why?
|
| ABO Blood-Group System | 1 | 1991 | 39 | 0.010 |
Why?
|
| Comorbidity | 1 | 1995 | 1540 | 0.010 |
Why?
|
| Acetanilides | 1 | 1970 | 11 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1991 | 300 | 0.010 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1990 | 39 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1991 | 330 | 0.010 |
Why?
|
| Diphenhydramine | 1 | 1990 | 31 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 1992 | 197 | 0.010 |
Why?
|
| Temporal Arteries | 1 | 1990 | 45 | 0.010 |
Why?
|
| Waiting Lists | 1 | 1992 | 238 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1989 | 87 | 0.010 |
Why?
|
| Microspheres | 1 | 1990 | 124 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1989 | 157 | 0.000 |
Why?
|
| Cholera Toxin | 1 | 1988 | 29 | 0.000 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1988 | 51 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1992 | 837 | 0.000 |
Why?
|
| Coronary Angiography | 1 | 1990 | 306 | 0.000 |
Why?
|
| Weight Gain | 1 | 1992 | 505 | 0.000 |
Why?
|
| Sympathectomy, Chemical | 1 | 1988 | 5 | 0.000 |
Why?
|
| Oxidopamine | 1 | 1988 | 13 | 0.000 |
Why?
|
| Patient Readmission | 1 | 1993 | 664 | 0.000 |
Why?
|
| Trachea | 1 | 1970 | 221 | 0.000 |
Why?
|
| Curriculum | 1 | 1995 | 921 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1992 | 593 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1988 | 331 | 0.000 |
Why?
|
| Substrate Specificity | 1 | 1988 | 367 | 0.000 |
Why?
|
| Hospital Planning | 1 | 1987 | 4 | 0.000 |
Why?
|
| Catalysis | 1 | 1988 | 304 | 0.000 |
Why?
|
| Aorta | 1 | 1970 | 407 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1992 | 820 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1989 | 306 | 0.000 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 1987 | 96 | 0.000 |
Why?
|
| Nitrates | 1 | 1985 | 87 | 0.000 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1989 | 701 | 0.000 |
Why?
|
| Heart Defects, Congenital | 1 | 1991 | 736 | 0.000 |
Why?
|
| Vasomotor System | 1 | 1984 | 43 | 0.000 |
Why?
|
| Yohimbine | 1 | 1984 | 9 | 0.000 |
Why?
|
| Phentolamine | 1 | 1984 | 14 | 0.000 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 1 | 1984 | 3 | 0.000 |
Why?
|
| Prazosin | 1 | 1984 | 24 | 0.000 |
Why?
|
| Potassium Chloride | 1 | 1984 | 33 | 0.000 |
Why?
|
| Papillary Muscles | 1 | 1983 | 13 | 0.000 |
Why?
|
| Transplantation, Isogeneic | 1 | 1983 | 17 | 0.000 |
Why?
|
| Rest | 1 | 1983 | 123 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1982 | 356 | 0.000 |
Why?
|
| Citric Acid | 1 | 1982 | 30 | 0.000 |
Why?
|
| Lidocaine | 1 | 1982 | 41 | 0.000 |
Why?
|
| Cimetidine | 1 | 1981 | 13 | 0.000 |
Why?
|
| Serotonin | 1 | 1984 | 318 | 0.000 |
Why?
|
| Thorax | 1 | 1981 | 41 | 0.000 |
Why?
|
| Membrane Potentials | 1 | 1982 | 260 | 0.000 |
Why?
|
| Morphine | 1 | 1981 | 128 | 0.000 |
Why?
|
| Prostaglandins | 1 | 1980 | 84 | 0.000 |
Why?
|
| Acetylcholine | 1 | 1980 | 183 | 0.000 |
Why?
|
| Cardiopulmonary Bypass | 1 | 1981 | 190 | 0.000 |
Why?
|
| Cattle | 1 | 1980 | 962 | 0.000 |
Why?
|
| Mediastinum | 1 | 1977 | 23 | 0.000 |
Why?
|
| Biopsy, Needle | 1 | 1977 | 189 | 0.000 |
Why?
|
| Pain | 1 | 1981 | 756 | 0.000 |
Why?
|
| Hodgkin Disease | 1 | 1977 | 134 | 0.000 |
Why?
|